Alzamend Neuro stockholders approve reverse stock split and Series C conversion at annual meeting

Alzamend Neuro, Inc.

Elected eight directors including William B. Horne, Milton C. Ault III, and others with substantial support; broker non-votes of 2,270,160.
Ratified Haskell & White LLP as independent auditor for fiscal year ending April 30, 2025; 4,255,027 for, 54,999 against.
Approved conversion of Series C Preferred Stock into common and warrants for up to $5M (less 5% discount); 757,391 for, 142,345 against.
Approved reverse stock split at ratio between 1:2 and 1:10, board to set exact ratio by April 24, 2026; 3,252,166 for, 1,077,493 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.